4 Stocks Trading Near 52-Week High With More Upside Potential

A Zacks screen highlights Cinemark, ConocoPhillips, Pebblebrook Hotel Trust and Chord Energy as momentum candidates trading within 20% of their 52-week highs, based on price momentum, valuation and earnings-growth filters. Pebblebrook raised its 2026 outlook to adjusted FFO of $1.88–$1.92 per share; ConocoPhillips targets $1 billion in 2026 capital and cost reductions, while Chord agreed to sell non-operated Marcellus assets for $550 million. Six-month returns were mixed, ranging from Chord’s decline of 3.6% to Pebblebrook’s gain of 53.3%, and the article notes risks including commodity-price swings and Cinemark’s absent formal earnings guidance.

Analysis

The screen is a positioning signal, not an independent valuation catalyst: four-week and 12-week momentum can persist, but the article supplies no multiples, estimate revisions, or positioning data to establish remaining upside. The more useful distinction is catalyst quality. PEB has a measurable operating path, but after a sharp rally its thesis increasingly depends on RevPAR and FFO delivering against raised expectations; a slowdown in urban group demand or higher financing costs could reverse the rerating. Its December debt funding is a near-term liquidity checkpoint, not evidence that leverage risk has disappeared. CNK’s holiday slate is a concentrated attendance bet: box-office strength can lift fixed-cost absorption, while weak releases leave remodel spending and debt as amplifiers on the downside. COP and CHRD are not diversifiers from one another: both retain oil-price exposure. CHRD’s asset sale may sharpen oil weighting but also increases basin concentration; higher per-barrel operating costs partially offset the portfolio simplification. COP’s capital-return case remains conditional on commodity cash flows and execution, with Iraq timing and geopolitics a distinct tail risk.

Over days, expect technical continuation or profit-taking to dominate absent new results. Over 1–3 months, track PEB’s realized RevPAR/FFO, CNK attendance and film performance, and CHRD’s post-divestiture guidance. Over 6–18 months, the key question is whether capital discipline and operating improvement convert into durable cash generation. The contrarian risk is that “near highs plus cheap versus peers” screens backward-looking multiples and can mislabel cyclical peak earnings as value; no supplied data verifies the screen’s valuation claims.

Key Decisions for Investors

• Do not buy the four-name basket solely on the screen. Require current valuation, estimate-revision and short-interest/flow data before sizing; the article’s promotional historical strategy returns are not evidence of forward edge.
• PEB: watch rather than chase after the large run. Reassess after December financing and the next operating update; weaken the thesis if RevPAR or adjusted FFO misses its stated outlook, or debt funding worsens versus the expected cash/FCF/term-loan mix.
• CNK: treat the holiday slate as an event-driven, asymmetric setup, not a proven secular growth call. Consider a small position only if attendance and premium-format monetization validate the spend; cut the thesis on disappointing holiday box office or materially weaker cash/debt trends.
• COP versus CHRD: avoid owning both as separate diversification bets. Prefer COP over CHRD only for investors seeking comparatively broader asset exposure; keep both exposures explicitly tied to oil prices, and revisit CHRD after the asset-sale close and updated guidance. Falsifiers include a sustained oil-price decline, delayed transaction closure, or weaker production/cost guidance.